Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.

Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.

CAPTEM (capecitabine and temozolomide) provided a high rate of disease control in patients with typical and atypical lung ...

A retrospective study found an association between elevated ALC and CAR+ T-cell counts and development of neurologic events in patients with r/r MM.

Real-world study confirmed that longer platinum-free interval was associated with better survival and prolonged 2L treatment duration in pts with endometrial cancer.

New research suggests that, among patients with neuroendocrine tumors, primary tumor sites differ by race, and overall survival outcomes differ by tumor site and gender.

Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

From 2003 to 2017, cancer incidence rates increased for several cancer types, with increases in younger and older adults for many cancers, according to a study.

For patients with early-stage cervical cancer, sentinel lymph node biopsy alone is noninferior to lymphadenectomy with respect to disease-free survival.